

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

## Amendment to CLAIMS

Claim 1 (Previously Presented): Use of one or more compounds having agonist activity to a 5-HT<sub>4</sub> receptor in the manufacture of a medicament for therapeutic or prophylactic treatment of disorders involving human bronchocontraction, chosen from the group consisting of asthma and disorders related thereto, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease, wherein said compounds have the capacity of reducing pathological bronchocontraction by at least 30%, preferably at least 60%, and most preferably at least 90%, and wherein said compound is chosen from the group comprising the following 5-HT<sub>4</sub> receptor agonists: benzamides containing the structural element 4-amino-5-chloro-2-methoxy benzamide based on metoclopramide, with the structural formula:



having a basic nitrogen in a side chain from the amide nitrogen, said basic nitrogen often being a part of a sterically locked system, preferably BRL 20627, BRL 24682, BRL 24924, Cisapride, Metoclopramide, ML-1035, Mosapride, R076186, Renzapride, RS 67506, Cinitapride, SB 205149, SC-49518, SC-52491, SC-53116, SDZ 216,454, TKS 159, Y-34959, YM-09151, YM-47813, and Zacopride;

5




15

20




30



35

the benzodioxan

5




SB 204070

10

the benzoic acid antagonist RS 23597 (an ester)  
transformed to an agonist by conversion to a ketone


15




20

e.g. preferably RS 67333 and RS 17017;  
naphtalimides; preferably RS 56532;

25



30




benzindolones;

35

compounds in which the amide function has been replaced with an oxadiazol ring;

5

10




preferably YM-53389;

15

benzimidazolone-1-carboxamides

20





preferably BIMU 1, BIMU 8, DAU 6215, and DAU 6236;

25

the carboamides

30




35


indols, preferably 5-methoxytryptamine, 2-methyl-serotonine, and 5-hydroxy-N,N-di-methyltryptamine;

compounds quaternized on the nitrogen in the side chain:

benzokinolinones



5-carboxamidotryptamine (5-CT), with the structural formula:




3-Me-8-OH-DPAT, 8-OH-DPAT (8-hydroxy-2-dipropyl-aminotetralin), RS 23597-190, RS 67532, RU 28253, SB 204070, Bufotenine, 5-MeO-N,N,DMT, GR 113,808,  $\alpha$ -methyl-5-HT, arylcarbamate derivatives of 1-piperidineethanol, arylcarbamate derivatives of 1-piperidineethanol, 4-amino-5-chloro-2-methoxybenzoic acid esters, 4-amino-5-chloro-2-methoxy-N-((2S,4S)-1-ethyl-2-hydroxy-methyl-4-pyrrolidinyl)benzamide, thiophene carboxamide derivatives 3 (a-j), 5-azabicyclo(x.y.z) derivatives, 2-piperazinylbenzoxazole derivatives, 2-piperazinylbenzothiazole derivatives (e.g. VB20B7), Sandoz compound 1b, clebopride, 2-piperidinmethylethers of benzimidazole, zelmac,


15

20


25




, particularly



2-piperidinmethylethers  
of bensimidazol





oxadiazalon based  
substance






kinolines

, particularly





, particularly








Q



, particularly



benzopyranes




and derivatives and pharmaceutically acceptable salts thereof.

Claim 2 (Previously Presented): Use according to claim 1, wherein said compound is VB20B7, RS67333, BIMU 1, BIMU 8, 5-methoxytryptamine, 5 Zacopride, RS56532, Mosapride, BRL 24924, or SC 53116.


Claim 3 (Previously Presented): Use according to any one of the previous claims, wherein said disorder involving bronchocontraction is asthma and disorders related thereto.

Claim 4 (Previously Presented): A method for treatment of disorders involving bronchocontraction, wherein said method comprises administering to a human or animal patient suffering from asthma and disorders related thereto, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease, a therapeutically effective amount of a compound according to any one of claims 1 and 2.


Claim 5 (Previously Presented): Use of one or more compounds having antagonist activity to a 5-HT<sub>3</sub> receptor, and derivatives and pharmaceutically acceptable salts thereof having antagonist activity to the 5-HT<sub>3</sub> receptor in the manufacture of a medicament for therapeutic or prophylactic treatment of disorders involving human bronchocontraction, chosen from the group consisting of asthma and disorders related thereto, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease, wherein said compounds have the capacity of reducing pathological bronchocontraction by at least 30%, preferably at least 60%, and most preferably at least 90%, and wherein said compound is chosen from the group comprising 5-HT<sub>3</sub> receptor antagonists



5




benztiazepines, preferably diltiazem



20

25




30

35


compounds also having 5-HT<sub>4</sub> receptor agonist activity, preferably benzamides

5



(cisapride, zacopride,  
mosapride, pancopride,  
BRL 24924, BMY 33462)

10 and




WAY 100289

15

2,3-dihydro-benzofuran-7-carboxamides

20




25

(preferably zatosetron=LY 277359, ADR 851);

1,4-benzoxazin-8-carboxamides

30



35

5



15

20




wherein the latter group reminds most of the specific 5-HT<sub>3</sub> antagonists, which contains the group



35


in different forms, such as

5




ondansetron

10



alose-tron




cilansetron

15

substances the structure of which has been inverted and the carbonyl group has been placed on the indoline nitrogen

20




FK 1052

25

30

also being an antagonist against both 5-HT<sub>3</sub> and 5-HT<sub>4</sub> receptors,


35



BRL 46470 A

bisindoles



5



YM 114

10 isoquinoline-1-ones

15





palonosetron (=RS 25259-197)

RS 42358-197

20 and the quinoline-3-carboxamides

25




30

WAY-SEC 579

Mirisetron (=WAY 100579),

quinoline-4-carboxylates


35



preferably KF 17643

5

10




preferably KF 18259;

15

benzimidazolones

20




preferably itasetron (DAU6215),

25

and the naphthimides

30




RS 56532

35 preferably RS 56532;


MDL 72222, which also is a specific 5-HT<sub>3</sub> antagonist;

5



; and


10



15


GK 128

20



Talipexole


25



30


iodophenpropit

35



thioperamide, and

5



2-piperidin- and 2-piperazin-  
benzimidazoles; and also

(R)-zacopride, 2-methyl-5HT, 3-(4-allylpiperazin-1-yl)-2-quinoxalinecarbonitrile, 4-Ph-N-Me-quipazine, 5-  
10 ((dimethylamino)methyl)-3-(1-methyl-1H-indol-3-yl)-1,2,4-oxadizole, 5,7-DHT, 5-[(dimethylamino)methyl]-3-(1-methyl-1H-indol-3-yl)-1,2,4-oxadizole, ADR-882, Amitriptyline, Anpirtoline, AS-5370, Batanopride, BIMU 1, BRL 24682, BRL 43694, BRL 46470 (=Ricasetron), BRL 47204,  
15 Bufotenine, CF 109203 (=BIM), Cizapride, Clozapine, CP-93318, Cyameazine, Cyproheptadine, Dolasetron mesilat (=MDL 73147 EF), Fluphenazone, Galdansetron, GR 38032 F, GR 67330, Granisetron (=Kytril=BRL 43694), GR-H, GYKL-48903, ICS 205-930, Indalpine, KAE-393/YM-114, KB-6922,  
20 KB-6933, KB-R 6933, KF-20170, Lerisetron, Lurosetron, LY 258-458, LY 278-989, LY-211-000, McNeil-A-343, MCPPE, MDL 72699, Mepyramine, Metergoline, Mianserin, MK 212, N-3256, NAN-190, N-methylquipazin, 3-(1-piperazinyl)-2-quinoxalinecarbonitrile, ONO-3051, Phenylbiguanide,  
25 Pitozifen, Prochlorperazine, QICS 205-930, R(+)zacopride, Renzapride, RG 12915, Ritanserin, RP 62203, RS-056812-198, RS-25259, RU 24969, S(-)Zacopride, S-apomorphin, SC-52491, SC-53116, SDZ 206-792, SDZ 206-830, SDZ 210-204, SDZ 210-205, SDZ 214-322, SDZ 322, SN-307, TFMPP, TMB 8,  
30 trifluoperazine, tropanyl-3,5-dimethylbenzoate, 3-tropanyl-indole-3-carboxylate methiodide, VA 21 B 7, Y 2513, SEC 579, BRL 46470 A, Pizotifen, Dolasetron (=MDL 74156), Galanolactone, GR 65 630, Ifenprodil, L-683877, Litoxetine, QX 222, Ramosetron (=YM 060), RS 56812, SDZ  
35 216-525, Trimebutine, GR 65630, Tropisetron, L-683,877, and pharmaceutically acceptable salts thereof with the same or essentially the same relaxation enhancing effect,

and derivatives and pharmaceutically acceptable salts thereof.

Claim 6 (Previously Presented): Use according to claim 5, wherein said compound is Tropanyl 3,5-dimethylbenzoate, MDL 72222, SDZ 216-525,  
5 ICI 169369, Zacopride, Tropisetron, Ramosetron, Ondansetron, Granisetron, Azasetron, Dolasetron, or Cilansetron.

Claim 7 (Previously Presented): Use according to any one of claims 5 and 6, wherein said disorder involving bronchocontraction is asthma and disorders related thereto.

Claim 8 (Previously Presented): A method for treatment of disorders involving bronchocontraction, wherein said method comprises administering to a human or animal patient suffering from asthma and disorders related thereto, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease, a  
15 therapeutically effective amount of a compound according to any one of claims 5 and 6.


Claim 9 (Previously Presented): Use of a composition comprising a combination of at least one compound with agonist activity to the 5-HT<sub>4</sub> receptor, and at least one compound with antagonist activity to the 5-HT<sub>3</sub> receptor, for the manufacture of a  
20 medicament for therapeutic or prophylactic treatment of disorders involving bronchocontraction, chosen from the group consisting of asthma and disorders related thereto, emphysema, chronic bronchitis, and chronic obstructive  
25 pulmonary disease, preferably asthma and disorders related thereto.

Claim 10 (Previously Presented): Use according to claim 9, wherein said composition has the capacity of reducing pathological bronchocontraction by at least 30%, preferably at least 60%, and  
30 most preferably at least 90%, and wherein said combination is chosen from the following groups of

a) 5-HT<sub>4</sub> receptor agonists:


benzamides containing the structural element 4-amino-5-chloro-2-methoxy benzamide based on metoclopra

mide, with the structural formula:




having a basic nitrogen in a side chain from the amide nitrogen, said basic nitrogen often being a part of a sterically locked system, preferably BRL 20627, BRL 24682, BRL 24924, Cisapride, Metoclopramide, ML-1035, Mosapride, R076186, Renzapride, RS 67506, Cinitapride, SB 205149, SC-49518, SC-52491, SC-53116, SDZ 216,454, TKS 159, Y-34959, YM-09151, YM-47813, and Zacopride;

benzoic acid esters:





preferably ML 10302, RS 57639, and SR 59768;  
a 2,3-dihydro-bensofuran-7-carboxamide compound,


preferably ADR 932, Prucalopride (=R 093877), and SK-951;



benzofuranes and benzothiophenes,



the benzodioxan



SB 204070

10



20




30



preferably YM-53389;

benzimidazolone-1-carboxamides



5



10

preferably BIMU 1, BIMU 8, DAU 6215, and DAU 6236;  
the carboamides

15



20


indols, preferably 5-methoxytryptamine, 2-methyl-  
serotonine, and 5-hydroxy-N,N-di-methyltryptamine;

25

compounds quaternized on the nitrogen in the side  
chain:


benzokinolinones

30




35


5-carboxamidotryptamine (5-CT), with the structural  
formula:




- 3-Me-8-OH-DPAT, 8-OH-DPAT (8-hydroxy-2-dipropylaminotetralin), RS 23597-190, RS 67532, RU 28253, SB 204070, Bufotenine, 5-MeO-N,N,DMT, GR 113,808,  $\alpha$ -methyl-5-HT, arylcarbamate derivatives of 1-piperidineethanol, arylcarbamate derivatives of 1-piperidineethanol, 4-amino-5-chloro-2-methoxybenzoic acid esters, 4-amino-5-chloro-2-methoxy-N-((2S,4S)-1-ethyl-2-hydroxymethyl-4-pyrrolidinyl)benzamide, thiophene carboxamide derivatives 3 (a-j), 5.azabicyclo(x.y.z) derivatives,
- 10 2-piperazinylbenzoxazole derivatives, 2-piperazinylbenzothiazole derivatives (e.g. VB20B7), Sandoz compound 1b, clebopride, 2-piperidinmethylethers of benzimidazole, zelmac,





2-piperidinmethylethers  
of bensimidazol





oxadiazalon based  
substance





kinolines








Q



, particularly




benzopyranes




and serotonin (5-HT) and derivatives and pharmaceutically acceptable salts thereof.


b) 5-HT<sub>3</sub> receptor antagonists:




benzazepines, preferably mirtazapine



benztiazepines, preferably diltiazem




and fentiazines




preferably perphenazine, stemetil;

compounds also having 5-HT<sub>4</sub> receptor agonist activity, preferably benzamides




(cisapride, zacopride,  
mosapride, pancropride,  
BRL 24924, BMY 33462)

and



WAY 100289


2,3-dihydro-benzofuran-7-carboxamides



(preferably zatosetron=LY 277359; ADR 851);

1,4-benoxazin-8-carboxamides

5




10

preferably azasetron (=Y25130);

benzimidazolones

15




20

preferably itasetron (=DAU 6215);

25

indazol-3-carboxamides

30




preferably N 3389, LY 278584, DAT 582;

35


wherein the latter group reminds most of the specific 5-HT<sub>3</sub> antagonists, which contains the group

5




10 in different forms, such as

15




ondansetron

20



alose-tron




cilansetron

25

substances the structure of which has been inverted and the carbonyl group has been placed on the indoline nitrogen

30




FK 1052

35

also being an antagonist against both 5-HT<sub>3</sub> and 5-HT<sub>4</sub> receptors,


5



BRL 46470 A

bisindoles

10





YM 114

15

isoquinoline-1-ones

20





25

palonosetron (=RS 25259-197)

RS 42358-197

and the quinoline-3-carboxamides

30




35

WAY-SEC 579

Mirisetron (=WAY 100579),


quinoline-4-carboxylates

5



10 preferably KF 17643


15



20 preferably KF 18259;

benzimidazolones

25



30


preferably itasetron (DAU6215),

35

and the naphthimides

5

10




RS 56532

preferably RS 56532;

15

MDL 72222, which also is a specific 5-HT<sub>3</sub> antagonist;


20



; and


25

30






GK 128

35



Talipexole



20 (R)-zacopride, 2-methyl-5HT, 3-(4-allylpiperazin-1-yl)-2-quinoxalinecarbonitrile, 4-Ph-N-Me-quipazine, 5-((dimethylamino)methyl)-3-(1-methyl-1H-indol-3-yl)-1,2,4-oxadizole, 5,7-DHT, 5-[(dimethylamino)methyl]-3-(1-methyl-1H-indol-3-yl)-1,2,4-oxadizole, ADR-882, Amitriptyline, Anpirtoline, AS-5370, Batanopride, BIMU 1, BRL 24682, BRL 43694, BRL 46470 (=Ricasetron), BRL 47204, Bufotenine, CF 109203 (=BIM), Cizapride, Clozapine, CP-93318, Cyameazine, Cyproheptadine, Dolasetron mesilat  
30 (=MDL 73147 EF), Fluphenazone, Galdanasetron, GR 38032 F, GR 67330, Granisetron (=Kytril=BRL 43694), GR-H, GYK1-48903, ICS 205-930, Indalpine, KAE-393/YM-114, KB-6922, KB-6933, KB-R 6933, KF-20170, Lerisetron, Lurosetron, LY 258-458, LY 278-989, LY-211-000, McNeil-A-343, MCPPP, MDL  
35 72699, Mepyramine, Metergoline, Mianserin, MK 212, N-3256, NAN-190, N-metylquipazin, 3-(1-piperazinyl)-2-quinoxalinecarbonitrile, ONO-3051, Phenylbiguanide,

Pitozifen, Prochlorperazine, QICS 205-930, R(+)zacopride, Renzapride, RG 12915, Ritanserin, RP 62203, RS-056812-198, RS-25259, RU 24969, S(-)Zacopride, S-apomorfin, SC-52491, SC-53116, SDZ 206-792, SDZ 206-830, SDZ 210-204, 5 SDZ 210-205, SDZ 214-322, SDZ 322, SN-307, TFMPP, TMB 8, trifluoperzine, tropanyl-3,5-dimethylbenzoate, 3-tropanyl-indole-3-carboxylate methiodide, VA 21 B 7, Y 2513, SEC 579, BRL 46470 A, Pizotifen, Dolasetron (=MDL 74156), Galanolactone, GR 65 630, Ifenprodil, L-683877, 10 Litoxetine, QX 222, Ramosetron (=YM 060), RS 56812, SDZ 216-525, Trimebutine, GR 65630, Tropisetron, L-683,877, and pharmaceutically acceptable salts thereof with the same or essentially the same relaxation enhancing effect, and derivatives and pharmaceutically acceptable salts 15 thereof.

Claim 11 (Previously Presented): Use according to claim 10, wherein the composition comprises the following combinations of a 5-HT<sub>4</sub> receptor agonist and a 5-HT<sub>2</sub> receptor antagonist: VB20B7 and Tropanyl 3,5-dimethylbenzoate, VB20B7 and MDL 72222, 20 RS67333 and Tropanyl 3,5-dimethylbenzoate, RS76333 and MDL 72222, VB20B7 and ICI 169369, RS67333 and ICI 169369, Zacopride and Tropanyl 3,5-dimethylbenzoate, Zacopride and MDL 72222, RS56532 and Tropanyl 3,5 dimethylbenzoate, RS56532 and MDL 72222, Itasetron and Tropanyl 3,5- 25 dimethylbenzoate, Itasetron and MDL 72222, VB20B7 and SDZ 216-525, and RS67333 and SDZ 216-525.

Claim 12 (Previously Presented): A method for treatment of disorders involving bronchocontraction chosen from the group consisting of asthma and disorders related thereto, emphysema, chronic 30 bronchitis, and chronic obstructive pulmonary disease, wherein said method comprises administering to a human or animal patient a therapeutically effective amount of a composition according to any one of claims 10 and 11.

Claim 13 (Previously Presented): A method for treatment of disorders involving 35 bronchocontraction chosen from the group consisting of asthma and disorders related thereto, emphysema, chronic

wherein said method comprises administering to a human or animal patient a therapeutically effective amount of a 5-HT<sub>4</sub> receptor agonist according to any one of claims 1 and 2 and a 5-HT<sub>2</sub> receptor antagonist according to any one of claims 5 and 6, either simultaneously or sequentially.

14-17 (canceled)

18. (new) Method of treating disorders involving human bronchocontraction, chosen from the group consisting of asthma and disorders related thereto, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease comprising:


administering one or more compounds having agonist activity to a 5-HT<sub>4</sub> receptor, wherein said one or more compounds have the capacity of reducing pathological bronchocontraction by at least 30%, preferably at least 60%, and most preferably at least 90%.

19. (new) Method of claim 18, wherein said one or more compounds are chosen from the group comprising the following 5-HT<sub>4</sub> receptor agonists: benzamides containing the structural element 4-amino-5-chloro-2-methoxy benzamide, optionally having a basic nitrogen in a side chain from the amide nitrogen, said basic nitrogen often being a part of a sterically locked system, preferably BRL 20627, BRL 24682, BRL 24924, Cisapride, Metoclopramide, ML-1035, Mosapride, RO76186, Renzapride, RS 67506, Cinitapride, SB 205149, SC-49518, SC-52491, SC-53116, SDZ 216,454, TKS 159, Y-34959, YM-09151, YM-47813, and Zacopride;


benzoic acid esters:  
preferably ML 10302, RS 57639, and SR 59768;

a 2, 3-dihydro-benzofuran-7-carboxamide compound, preferably ADR 932, Prucalopride (=R 093877), and SK-951;

benzofuranes and benzothiophenes,  
the benzodioxan





the benzoic acid antagonist RS 23597 (an ester) transformed to an agonist by conversion to a ketone




e.g. RS 67333 and RS 17017.

naphtalimides, preferably RS 56532;



benzindolones;

compounds in which the amide function has been replaced with an oxadiazol ring;





preferably YM-53389;

benzimidazolone-1-carboxamides

preferably BIMU 1, BIMU 8, DAU 6215, and DAU 6236;

the carboamides




Indols, preferably 5-methoxytryptamine, 2-methylserotonine, and 5-hydroxy-N,N-dimethyltryptamine;


Compounds quartenized on the nitrogen in the side chain:

bensokinolinones


5-carboxamidotryptamine (5-CT), with the structural formula:




5-HT, 3-Me-8-OH-DPAT, 8-OH-DPAT (8-hydroxy-2-dipropylaminotetralin), RS 23597-190, RS 67532, RU 28253, SB 204070, Bufotenine, 5-MeO-N,N,DMT, GR 113,808,  $\alpha$ -methyl-5-HT, arylcarbamate derivatives of 1-piperidineethanol, arylcarbamate derivatives of 1-piperidineethanol, 4-amino-5-chloro-2-methoxybenzoic acid esters, 4-amino-5-chloro-2-methoxy-N-((2S,4S)-1-ethyl-2-hydroxymethyl-4-pyrrolidinyl)benzamide, thiophene carboxamide derivatives 3 (a-j), 5.azabicyclo(x.y.z) derivatives, 2-piperazinylbenzoxazole derivatives, 2-piperazinylbenzothiazole derivatives (e.g. VB20B7), Sandoz compound 1b, clebopride, 2-piperidinmethylethers of benzimidazole, zelmac,




, particularly



2-piperidinmethylethers  
of bensimidazol





oxadiazalon based  
substance






kinolines

, particularly





, particularly








Q



, particularly



benzopyrrolanes



and derivatives and pharmaceutically acceptable salts thereof.

20. (new) Method of claim 18, wherein said one or more compounds is VB20B7, RS67333, BIMU 1, BIMU 8, 5-methoxytryptamine, Zacopride, RS565323, Mosapride, BRL 24924, or SC 53116.

21. (new) Method according to claims 18-20, wherein said disorder involving bronchocontraction is asthma and disorders related thereto.